Navigation Links
With Bone Marrow Transplants Rising, New Therapy Gives Hope to Those Over 55
Date:1/8/2014

NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S. They are the only potential cure for many blood cancers such as acute myeloid leukemia (AML) in older patients. The procedure is technically called hematopoietic stem cell transplantation (HSCT) and can be either a bone marrow transplant (BMT) or transplant of blood stem cells isolated from peripheral blood (PBSC). In either case, it involves transplanting cells capable of restoring normal bone marrow function into a patient.

An increasing number of HSCT patients are over age 55, but many in this group who need it are ruled ineligible. This is because the high-dose chemotherapy traditionally preceding HSCT—standard therapy for younger patients—is often deemed too harsh even for healthy looking older people. Indeed, in certain indications, less than 10 percent of those 55+ survive more than a year after conventional HSCT.

Since more than half of AML patients are over 65 years old, new tactics are needed. For example, what if a patient's existing bone marrow could be "prepared" prior to the transplant in a way that eliminated the need for high-dose chemotherapy? This promising approach is being pursued by an innovative New York City-based biotech company, Actinium Pharmaceuticals, Inc.

Actinium's lead compound, Iomab™-B, has been successfully harnessed as a "myeloconditioning" agent in Phase 1/2 trials involving more than 250 patients including cases of incurable blood cancers such as AML resistant to available therapies. It has demonstrated the ability to prepare such patients for bone marrow transplants when no other treatment was indicated. The targeting part of Iomab™-B is a monoclonal antibody that targets CD45, an antigen widely expressed on white blood cells but not on other tissues.

Very significantly, treatment with Iomab™-B prepares a patient for bone marrow transplant in only 10 days, compared to approximately six weeks required with traditional care—a potentially vital difference in the face of a fast-evolving cancer.

"The only potentially curative treatment option for older AML patients is bone marrow transplant, but the majority of patients over age 55 are ineligible for conventional care due to health reasons and/or severity of their disease," says Kaushik J. Dave, Ph.D., President and CEO of Actinium Pharmaceuticals, Inc. "We believe Iomab™-B offers a positive step toward their continued treatment. Almost all patients are eligible, and preliminary studies indicate their survival rates are significantly higher as a result. It also can help prepare older patients for bone marrow treatment who have survived chemo but whose AML either was not cured or returned."

On the strength of results showing its potential in Phase 1/2 trials, the company is poised to begin a Phase 3 trial during 2014. The primary endpoint will be the rate of durable complete remission among the treated patients. A series of physician-led trials involving Iomab™-B is also ongoing.

For more information, visit www.actiniumpharmaceuticals.com, who paid for the writing and dissemination of this release.

Contact:  Laura Radocaj, Dian Griesel Int'l.  212.825.3210


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
3. The Princess Margaret BMT Program Chooses Remedy Informatics Blood and Marrow Transplant & Cell Therapy Solutions to Power their fight Against Cancer
4. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
5. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
6. Alpha and Omega Gene Therapy Eye Creams Scientific Blend Removes Years of Damage
7. FDA Clears the Provant Therapy System for Use by Patients with Metallic Implants
8. Norgine and Innovacell Enter Into an Exclusive Licensing Agreement for ICEF15 - An Innovative Personalised Cell Therapy to Treat Faecal Incontinence
9. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
10. FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes
11. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):